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Abstract: Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide,
representing 13% of all cancers. The role of epigenetics in cancer diagnosis and prognosis is
well established. MicroRNAs in particular influence numerous cancer associated processes including
apoptosis, proliferation, differentiation, cell-cycle controls, migration/invasion and metabolism.
MiRNAs-137 and 342 are exon- and intron-embedded, respectively, acting as tumour-suppressive
microRNA via hypermethylation events. Levels of miRNAs 137 and 342 have been investigated here
as potential prognostic markers for colorectal cancer patients. The methylation status of miRNA-137
and miRNA-342 was evaluated using methylation-specific (MSP) polymerase chain reaction (PCR)
on freshly frozen tissue derived from 51 polyps, 8 tumours and 14 normal colon mucosa specimens.
Methylation status of miRNA-137 and miRNA-342 was significantly higher in tumour lesions
compared to normal adjacent mucosa. Surprisingly, the methylation frequency of miR-342 (76.3%)
among colorectal cancer patients was significantly higher compared to miR-137 (18.6%). Furthermore,
normal tissues, adjacent to the lesions (N-Cs), displayed no observable methylation for miRNA-137,
whereas 27.2% of these N-Cs showed miRNA-342 hypermethylation. MiRNA-137 hypermethylation
was significantly higher in male patients and miR-342 hypermethylation correlated with patient age.
Methylation status of miRNA-137 and miRNA-342 has both diagnostic and prognostic value in CRC
prediction and prevention.
Keywords: colorectal cancer; microRNA; methylation; miRNA-137; miRNA-342; precursor
colon/rectum polyps
1. Introduction
Colorectal cancer (CRC) is a major health burden comprising 13% of new cancer cases diagnosed
worldwide annually, ranking as the third most prevalent and fourth most frequent cause of
Biomolecules 2019, 9, 519; doi:10.3390/biom9100519 www.mdpi.com/journal/biomolecules
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cancer-related mortality. CRC is responsible for more than 600,000 deaths each year and morbidity
and mortality rates continue to increase, partly due to lack of appropriate and reliable early detection
methods [1–4]. In the majority of cases, CRC occur sporadically and is not related to genetic
predisposition or family history. However, 20–30% of patients have a positive family history of CRC
and 5% of these patients show Mendelian inheritance [5].
Early detection of non-invasive tumors using DNA/RNA-based methodologies remains an exciting
and emerging area of research into CRC screening methodologies. These methods are essential tools
for researchers and practitioners to characterize the noninvasive tumors, plan for individualized
treatments and track tumor treatment efficacy and prognosis in CRC. Of such technics, gene-specific
DNA methylation patterning is perhaps the most attractive [6]. DNA methylation mainly occurs in
CpG islands and as DNA methylation is more stable in comparison to mutations, it has been considered
as a favorable area for biomarker exploration and identification [1,5,6].
Genes affected by aberrant hypermethylation are not confined to classical coding-based tumour
suppressors; non-coding sequences such as microRNA genes are also affected and are significant players
in tumorigenesis [7,8]. DNA methylation has received significant recent attention as a promising tool
for cancer detection and prevention with promise for reducing mortality rates [8–11].
Eslamizadeh et al. (2018) [12] reported that microRNA expression levels correlate with different
stages of CRC, hence they could provide new insight into tumour development, whilst being suitable
and reliable biomarkers for CRC diagnosis and prognosis. Indeed, Feinberg and Vogelstein (1983) [13]
previously showed DNA hypomethylation (mainly at CpG islands) at the early stages of CRC, combined
by hypermethylation and inactivation of tumor suppressor or DNA repair genes.
Epigenetic changes have recently been associated with the normal mucosa aberrant crypt focus
(ACF)-adenoma-carcinoma sequence, which itself plays an important role in CRC development [14].
DNA methylation status, therefore, appears to be a fundamental factor in carcinogenesis of CRC process.
Specifically, it has previously been shown that hypermethylation of MMR genes results in MSI-sporadic
CRC; through CpG Island Methylator Phenotype (CIMP), this was linked with chromosomal instability
(CIN) in colon malignancy (where promoter methylation of GATA4, GATA5, p16 was previously
shown to result in chromosomal loss or gain); changes in methylation status have been reported in a
variety of genes relevant to these particular pathways [15–20]. Moreover, to date many studies have
highlighted the potential benefits of implementing DNA-based aberrant methylation status assays
in different biologic fluids as strategies for colorectal carcinoma early detection [21]. Lyberopoulou
et al. (2017) [22] studied the methylation profile of CRC-specific genes, vimentin (VIM) and secreted
frizzled-related protein 2 (SFRP2) in circulating tumor cells’ (CTCs) DNA. The authors confirmed
essential roles for VIM and SFRP2 in important signaling pathways such as growth, proliferation,
invasiveness, epithelial to mesynchymal (EMT) phenotype and stemness, using CTCs of CRC patients.
They also showed CTCs to be a promising tool in cancer diagnostics, particularly for VIM (76.9%
methylated, compared to the 53.8% in tissue samples).
It has been proposed that cancer cells rewire DNA methylation patterns of specific genes (either
in their promoter region or in the gene body) to induce expression of oncogenes, to support their
aggressiveness and silence the expression of tumor suppressors, for instance, to surmount apoptosis.
This phenomenon has been specifically (but not exclusively) reported in context of CRC [22].
MicroRNAs (miRNAs = miRs) control >30% of regulatory pathways related to human gene
expression and >500 miRs have been identified to date [23]. Growing bodies of evidence suggest that
miRNAs are commonly dysregulated in human malignancies including CRC [11,22–25].
miRNA-137, a 23 bp, highly conserved miRNA among vertebrates [26,27] is one of the
10% intragenic miRNAs located in 1p21.3 and is embedded within an expanded CG island of
a non-coding gene whose transcript is a lncRNA (AK094607; also called BRAMY2014205 and
MIR137HG, counted as primary miR-137 coding sequence) [28,29]. Its downregulation due to proximal
promoter hypermethylation has been reported in many cancer types including gastric cancer [30–32]
melanoma [33] neuroblastoma [34,35] squamous cell carcinoma of head and neck (SCCHN) [36–39]
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and CRC [40–43]. MiRNA-342 (a 21bp miRNA) is encoded within an intron of a protein-coding gene
(EVL) on chromosome 14q32.2. The 5‘UTR of EVL contains a dense CpG island. It has been proposed
previously that methylation status could be utilized as a non-invasive CRC biomarker [43–48]. MiR-137
and miR-342 are integral microRNAs implicated in as MSI-targeting microRNAs in CRC [49]. Taking
into consideration that MSI status is one of the fundamental main initial events in carcinogenesis
of colorectal lesions and tumor budding, we hypothesized the possibility of these two microRNAs
deregulation may be useful as a biomarkers for the early detection of pre-cancerous and malignant
lesions. As the role of miRNA-137/-342 promoter hypermethylation in colorectal lesions has not been
fully investigated properly, the preliminary objective of this study was to evaluate the methylation
status of miR-137 and miR-342 in different precursor and tumour lesions of colorectal tissues, tracing
any possible correlations of this occurrence with CRC risk factors and assessing any significant patterns
of methylation between CRC and normal colonic tissues.
2. Materials and Methods
2.1. Sampling
Specimens were obtained with patient consent during September 2016 to February 2017 from
random patient samples referred to the Research Institute for Gastroenterology and Liver Diseases
(RIGLD), Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, who had
undergone a colonoscopy procedure for either screening or polypectomy purposes. All procedures
performed in this study involving human participants were in accordance with the ethical standards of
the institutional research committee and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards. Ethical approval was accepted on April 2016 by the ethical board of the
Research Institute of RIGLD (project identification code: 2347-231) and Informed consent was obtained
from all individual participants included in the study. In this study, 59 endoscopically-derived lesions
and 14 normal colonic mucosas were evaluated. Sampling was done randomly during colonoscopy
procedures, disregarding of lesion size, anatomic site and number of lesions in the affected colon. The
specimens were flash frozen in liquid nitrogen and stored at −80 ◦C for further evaluation. Non-Persian
patients and those who had positive history of chemo and radio therapies or cancer-related surgeries
were dismissed according to study exclusion criteria.
2.2. Genomic DNA Extraction
DNA extraction was performed utilizing Qiagen QIAamp DNA Mini Kit (Cat. 51324, Qiagen,
Germany) according to the manufacturer’s instructions. The concentration of the extracted DNA was
measured by Nanodrop (Labtech; UK) @260 and 280 nm.
2.3. Sodium Bisulfite Treatment
Each DNA template was incubated with sodium bisulfite solution in order to achieve two
distinctive and detectable template strands which are different merely upon their methylation status
using Qiagen EpiTect Bisulfite Kit (Cat. 59104, Qiagen, Germany).
2.4. Methylation-Specific Polymerase Chain Reaction (MSP)
Methylation-specific polymerase chain reaction (MSP) was conducted using two primer pairs;
each specifically designed to attach to methylated or unmethylated strands. Segments were amplified
in a total volume of 12.5 µL (Table 1) according to reactions profiles detailed in Table 2. Sequence,
relative length, GC content and annealing temperature of primers are shown in Table 3 [27].
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Table 1. Reagents and volumes utilized for preparing the polymerase chain reaction (PCR) master mix.
Final Concentration Volume/Reaction (µL) Reagent
Distilled Water 5.45 -
10x Hot Start Buffer 1.25 1x
5X Q buffer 2.5 1x
25 mM MgCl2 0.25 1.5–5 mM
dNTP * (10 mM of each) 0.25 200 µM of each dNTP
Primer Forward (M and U) 0.75 0.1–0.5 µM
Primer Reverse (M and U) 0.75 0.1–0.5 µM
Template 1.2 1 µg/100 µL reaction
Hot Start Taq Polymerase 0.1 2.5 units/reaction
Final Volume 12.5 -
* deoxyribonucleotide triphosphate.
Table 2. Thermocycler-optimized PCR program for miR-137 and miR-342 genes.







Primary denaturation 15 95 15′ 95
Cycles
Denaturation 1 95 * 30 92 **
Annealing 35 56 * 45 64 **
Extension 1 72 * 30 72 **
Final Extension 10 72 10 72
* Number of cycles = 40, ** Number of cycles = 45.
Table 3. Methylation-specific PCR primer properties.
Annealing
Temperature (◦C) %CG Length Sequence Primer
53.2 57.9 19 5′-TAGCGGTAGTAGCGGTAGC-3′
miRNA-137-M*
(Forward)
52.4 47.6 21 5′-CTAATACTCTCCTCGACTACG-3 miRNA-137-M*(Reverse)
52.4 47.6 21 5′-TAGTGGTAGTAGTGGTAGTGG-3′
miRNA-137-U*
(Forward)
51.1 40.9 22 5′-CTAATACTCTCCTCAACTACAC-3′ miRNA-137-U*(Reverse)
71.15–80.47 44 43 5′-GCGGTCCCAAAAGGGTCAGTTATTTTCGTTCGTTTCGTTTTTC-3′ miRNA-342-M*(Forward)
72.50–81.79 51 41 5′-GCGGTCCCAAAAGGGTCAGTAAATACGCGCGTTACTATTCG-3′ MiRNA-342-M*(Reverse)
59.51 58.99- 35 45 5′-GCGGTCCCAAAAGGGTCAGTTATTTTTGTTTGTTTTGTTTTTTGT-3′
miRNA-342-U*
(Forward)
69.92–79.44 42 45 5′-GCGGTCCCAAAAGGGTCAGTTAAAATACACACATTACTATTCACC-3′
miRNA-342-U*
(Reverse)
* M: Methylated; U: Un-methylated; Underlined sequence: Universal.
CpG-methylated HeLa Genomic DNA (New England BioLabs; Cat.#N4007S) was utilized as
positive control for methylation, negative control was fully unmethylated DNA (EpiTect PCR control
DNA; Qiagen). Two separate temperature gradients were performed to assess optimal annealing
temperature for both forward and reverse primers (miR-137; 57 ◦C, miR-342; 63 ◦C). The specific band
size observed was 140 bp and 210 bp, respectively. PCR products were run on 2% agarose gels and
visualized via EtBr fluorescence (Figure 1).
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or alcohol (Table 4 and supplementary Tables 1 and 2). 
Synchronous assessment of dysplasia degree and the histological-pathological state of the 
samples showed that except for invasive adenocarcinomas (concordant with tumour lesions), the 
majority of the lesions had lower degrees of dysplasia, disregarding their defined sub-types (Figure 
2), this finding suggests that most cases evaluated in this study were in early carcinogenesis. 
Figure 1. Case specimen methylation-specific polymerase chain reaction (MSP) for miR-137(A) and
miR-342(B) visualized using 2% agarose gel and 50 bp ladder. For each sample, two wells ere arranged
named U and M wells. Presence of a band in M or U well illustrates methylation of the concordant
strand. Presence of two bands in both M and U wells show Hemi methylated alleles which are believed
to be due to contamination with the normal colonic mucosa.
2.5. Statistical Analysis
Dataset was analysed using SPSS.21 (manufacturer), utilizing descriptive analysis (including
chi-square and Fisher‘s exact test). Possible significant correlations between methylation status of
miR-137/-342 and demographic, pathologic, clinical, lifestyle and sy ptom-related features were
thereby evaluated (Supplementary Tables S1 and S2). Selected features were chosen following
consultation with an epidemiologist expert and were based on World Health Organization (WHO)
criteria for CRC [50]. Furthermore, the presence of any significant correlations between methylation
of miR-137 and miR-342 and quantitative traits such as patient’s age and BMI was evaluated using
independent t-test (Supplementary Table S3). Normalization of the quantitative traits was assessed
using one sample Kolmogorov–Smirnov test. Traits were also compared between distinct polyp
sub-types using one-way analysis of variance (ANOVA).
3. Results
The clinical, pathological, demographic and other characteristics of participants in this study are
shown in Table 4. Despite randomized sampling, the majority of samples (39%) were 1–10 mm diameters
and were the only lesions detected in the colon and rectum as a whole. Furthermore, the majority of
the patients were Farsi ethnics, primarily educated and not addicted to opium, smoking or alcohol
(Table 4 and supplementary Tables S1 and S2).
Synchronous assessment of dysplasia degree and the histological-pathological state of the samples
showed that except for invasive adenocarcinomas (concordant with tumour lesions), the majority of
the lesions had lower degrees of dysplasia, disregarding their defined sub-types (Figure 2), this finding
suggests that most cases evaluated in this study were in early carcinogenesis. According to our findings,
miR-137 and miR-342 methylation was significantly higher in tumour lesions in comparison with
their normal adjacent mucosa p = 0.002 and p = 0.02, respectively. The methylation frequency among
patients was 18.6% for miR-137 and 76.3% for miR-342. Although 27.27% of normal adjacent mucosa
specimens were also displayed methylated miR-342 regions, none showed methylation of for miR-137.
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Table 4. Frequency of the clinic-pathological features of the specimens.
Frequency (% and Number







Villous, juvenile and ulcerative lesions 5.1%—(3)
Other serrated types 3.4%—(3)
Dysplasia degree Low-grade dysplasia 59.3%—(3–5)
High and moderate dysplasia 40.7%—(24)
Anatomic site and
location in colon
Rectum and sigmoid 40.7%—(24)
Descending colon 22%—(13)







17–45 yrs. 25.4% (15)
45–65 yrs. 45.8% (27)
More than 65 yrs. 28.8% (17)
Body mass index (BMI)
Normal (18.5–25) 27.1% (16)
Overweight (>25) 71.2% (42)
Underweight (<25) 1.7% (1)





Hypertension Positive 16.9% (10)
Negative 83.1% (49)
Nonsteroidal
anti-inflammatory drugs Positive 20.3% (12)
(NSAIDs) intake Negative 79.7% (47)
Smoking Positive 23.7% (14)
Negative 76.3% (45)





Regular exercise Positive 54.2% (32)
Negative 45.8% (27)





Normal specimens derived from non-lesion normal controls were entirely unmethylated.
Furthermore, we detected a significantly higher frequency of miR-137 methylation among males in
comparison with female CRC patients (p = 0.002). Also, there was a statistically significant positive
correlation between dysplasia degree and methylation status of miR-137 (0.016); 8.6% of the low
grade-dysplastic samples depicted methylated state. In addition, patients with positive family history
of colorectal cancer or other gastrointestinal-related cancers showed significantly higher frequencies of
miR-137 methylation in comparison with patients with no family history (p < 0.0001).
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Figure 2. Synchronous assessment of dysplasia degree and the pathological state of the specimens.
For iR-342, independent t-test results indicated an age-related hypermethylation pattern
(p < 0.001). miRNA-342 status was also in positive correlation with the presence of chronic constipation
in patients (p = 0.021). The crosstabs evaluated are shown in Supplementary Table S3. Comparing
the miR-137 methylation status between different sub-types of lesions (according to their pathological
report sheet), we observed a higher methylation frequency among villous-type polyps (Table 5);
an observation that proposed miR-137 methylation could at least in a part depend on distinct aetiology
and path ay of villous-lesion for ation (in co parison to non-villous types) and to a lesser degree,
on inor on dysplasia state and degree. n the other hand, e observed high iR-342 ethylation
frequency for hyperplastic polyps (Table 5). These results strongly suggest distinct aberrant methylation
status positively correlating with CRC progression in miRNAs 137 and 342.
able 5. Pro oter ethylation status of distinct colon lesions studied.
Pathology Report









Tubular adenoma polyps 15.6% 84.4% . 18. %




28.6% 71.4% 75.7% 14.3%
Ulcerated, juv nile and
retention polyps 20% 80% 20% 80%
Hyperplastic polyps 9.1% 90.9% 81.8 18.2%
Other serrated polyps 0% 100% 100% 0%
Synchronous assessment of both miRNA loci together suggested 20.3% of patients were
methylation-intact for both genes, 64.4% were methylated for at least one of these loci and 15.3% were
methylated for both.
4. Discussion
In the recent era of research, efforts to configure and validate miRNA-based biomarkers have
evolved significantly due at least in a part to the fact that in comparison with classic gene biomarkers,
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their alternation is much more tissue-specific. As a result, smaller evaluations can provide robust
indications of promising detection and prognostic methodologies. Their application is also more
accurate and less costly [44,51–55].
miRNA biomarker validation must involve thorough assessment using distinct precursor lesion
types. Therefore, we have provided evidence for the exon-embedded miR-137 and intron-embedded
miR-342 locus methylation status in tumour and polyp lesions of colon and rectum samples with
distinct pathological sub-types. Furthermore, in a case-control study, we compared this status between
tumour lesions and their adjacent normal mucosa. We also analysed normal colonic mucosa of a small
population of lesion-free, unaffected patients. In addition, an accurate, comprehensive assessment
of a possible correlation between demographic, pathological, clinical, lifestyle and symptom-related
features was conducted. Tumour suppressive roles of miR-137 and miR-342 and their epigenetic
roles in oral cancer and glioblastoma cell lines have been demonstrated previously [56–60]. Although
there are very few previous studies to which the role of miR-137 and miR-342 in triggering CRC is
referred, their downregulation has been reported in colon and gastric cancers [30,40]. Interestingly,
upregulations of miR-137 and miR-342 have been reported for oral squamous cell carcinoma and acute
promyelocytic leukaemia [61–64].
Chen et al. [65] through a follow-up cohort study demonstrated that miR-137 normal expression
levels correlate with better survival rates in CRC patients. This has also been suggested for SCCHN
patients and stage IV melanoma patients [36,66,67]. Ariel Bier et al. (2013), [59] detected promoter
hypermethylation of miR-137 in glioblastoma specimens. Although their relative sample size was small
(8 glioblastoma and 8 relevant normal), their methylation analysis technique was truly locus-specific
and quantitative, with higher specificity in comparison with the MSP technique we utilized in the
current study. However, this study used DNA extracted from formalin-fixed paraffin-embedded
(FFPE) tissues and it is believed that this would negatively influence the actual methylation status of
the tissue [67,68].
In another study by Balaguer et al. (2010) [40], average methylation levels were reported as
33.09% for adenomas, 31.67% for CRCs, 10.27% for normal adjacent mucosa (N-Cs) and 7.7% for
normal mucosa controls (N-Ns), respectively. Concordant with our study, methylation frequency of
miR-137 in tumours was significantly higher than their adjacent normal tissues (N-C) (P < 0.0001). This
observation indicates cancer-specificity of miR-137 (i.e., Methylation of miR-137 preferably happens in
neoplastic tissues and the methylation observed in normal mucosa is not due to aging) [69–74]. In both
studies, Methylation of miR-137 was not concordant with aging for N-N or N-C specimens. Incidence
of methylation in N-Cs and not in N-Ns could be an indication that methylation-related field defects
may exist in CRC.
In our study, we did not detect any significant differences in methylation levels of polyp and tumour
specimens (p = 0.141) which is concordant with the Blaguer group’s study (p = 0.8352); this observation
recommends that methylation of this miR-137 is an early event in colorectal carcinogenesis. Taking
into account that epigenetic modifications are highly influenced by lifestyle and geographical traits
of different populations, we excluded patients of non-Persian nationality from our study. Which is
considered an improvement on the Balaguer et al. study [40], which utilized samples taken from
two distinct populations (Japanese and Spanish), a factor that certainly causes errors and bias in
referring the methylation status solely to cancer (especially due to indistinct mixture proportions of
two populations).
Tissue-specificity of miRNA-137 has been previously and separately demonstrated [29,40],
in colorectal cancer and oral lichen planus (OLP) syndrome, confirming that miRNA-137 could have
value for CRC screening. MiR-137 was selected for this study due to its fundamental role in cell
cycle control [71]; in addition, promoter hypermethylation of miR-137 in colorectal carcinoma tissues
had been reported [40,41]. Langevin et al. in 2010 showed significant correlation between miR-137
methylation status and female sex (p = 0.007) [38,39]. Inversely, in the current study this event
was shown to be correlated with male sex (p = 0.002), which is in agreement with the Dang et al.
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study [29]. This illustrates cancer-specificity of miR-137 epigenetic signatures despite its common
down-regulation in most of the cancer types. Therefore, the level of this down-regulation and its
correlation with demographic factors such as sex and age has different implications in different cancer
types. Gender-related hypermethylation could be due to sex hormone effects and physiological
differences among target organs in both sexes.
To our knowledge, no study has previously shown any correlation between family history of
CRC and degree of dysplasia with methylation status of miR-137. Bandres et al. (2009) [72] evaluated
the methylation status of miR-137 in colorectal cancer cell lines and primary colorectal tumours
and their adjacent normal tissues using MSP technic [72–75] identifying field defects in colorectal
carcinogenesis. Regarding the high frequency of hypermethylation in miRNA loci, they proposed
aberrant microRNA-methylation as a promising and putative tumour marker. MiR-137 methylation
was observed for all tumour specimens (31 of 31) and 23% of (7 of 31) normal adjacent tissues.
However, we observed 37.5% of tumour specimens to be methylated and no methylated normal
adjacent specimens were observed. Unfortunately, this study did not manage to evaluate polyps which
are defined as precursors of CRC.
Grady et al. (2008) [75] reported that has-miR-342 expression was silenced due to aberrant
methylation in a CpG island of the 5‘ region of its target sequence (EVL). They conducted MSP on
CRC and non-CRC cell lines separately and methylation of miR-342 was exclusively seen in CRC cell
lines [75,76]. They then used MSP to assess the miR-342 methylation status of 9 adenomas, 42 CRC
samples and their normal adjacent mucosa. They observed that 76% of tumours and 67% of adenomas
were methylated; an observation that was in concordance with our results. They also detected 56%
methylation in their normal adjacent mucosa, an observation that indicates methylation-related field
defect phenomenon and is ascertained by our study. No demographic features were assessed in
their study.
Age-related hypermethylation and miRNA-dysregulation due to aging have been reported for
many genes in various cellular contexts [77–85]. Moreover, emerging evidence supports the existence
of epigenetic changes in other age-related conditions such as age-related macular degeneration,
here associated with aberrant histone modifications and alterations in chromatin structure. Indeed an
age-related effect has been corroborated in the current study for miR-342 hypermethylation in CRC.
The positive correlation between miR-342 hypermethylation and the presence of chronic
constipation suggests that due to the slower shedding rate of epithelial cells of the GI-track in
these patients, apoptosis is prolonged, and the possibility of cancer-related changes enhanced.
One of the limitations of questionnaire-based assessments is lack of patient compliance. Moreover,
inaccessibility to a homogenous statistical population from the aspects of lesion type, disease duration
and type/duration of a patient’s proneness to detrimental environmental factors (such as alcohol,
smoking, drug use, etc.) limits the robustness of results; increasing the sample size improving
methodological accuracy when selecting a particular population is highly recommended [86,87].
In order to ensure the possibility of using miR-137 and miR-342 methylation status as a non-invasive
early detection biomarker, it would be important to first repeat the study using blood samples
obtained from the same lesion-bearing patients. Moreover, evaluating the methylation status of other
down-regulated microRNAs in a panel may provide much more specific and sensitive results in early
diagnosis of CRC epigenomics [88,89]. Ultimately, due to complex and heterogeneous pathways
included in down-regulation of tumour suppressor genes in cancerous tissues, assessing the expression
level of these miRNA loci in the same specimens could elucidate whether the methylation observed
has caused its potential relative downregulation or not.
5. Conclusions
Our study strongly suggests that miR-137 and miR-342 are frequently methylated in CRC; therefore,
they are a good supplement for previous studies and could be useful for better understanding of
miRNA regulatory mechanisms in CRC. Results would help better appraise these putative biomarkers
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for detecting the lesions with higher malignancy potential, especially in the pre-symptomatic stage.
This research shows an age-related effect for miR-342 hypermethylation in CRC but for a comprehensive
and accurate assessment of the impact of age- and indeed sex-related factors on methylation status in
CRC-related malignancies, age-matched and sex-matched controls are essential. However, research
in this area is currently limited to the logistical/cultural difficulties associated with obtaining ideal
sample sets.
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